SEARCH

SEARCH BY CITATION

References

  • 1
    World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Toward Universal Access. Recommendations for a Public Health Approach. Anonymous, ed. Geneva: World Health Organization, 2006, 128 pp.
  • 2
    Ministry of Health Malawi. Treatment of AIDS: Guidelines for the Use of Antiretroviral Therapy in Malawi, 2nd ed. Anonymous, ed. Lilongwe: Malawi Ministry of Health, 2006, 155 pp.
  • 3
    Department of HIV and AIDS Ministry of Health. Quarterly Report of the Antiretroviral Treatment Programme in Malawi with Results up to 31st December 2008. Department of HIV and AIDS MoH, ed. Lilongwe, Malawi Ministry of Health, 2008.
  • 4
    Ministry of Health Malawi. Treatment of AIDS. Guidelines for the Use of Antiretroviral Therapy in Malawi, 3rd ed. Lilongwe: Malawi Ministry of Health, 2008.
  • 5
    Eron JJ Jr., Bartlett JA, Santana JL et al. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J Acquir Immune Defic Syndr 2004; 37: 15811583.
  • 6
    Castagna A, Danise A, Menzo S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006; 20: 795803.
  • 7
    Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269: 696699.
  • 8
    Campbell TB, Shulman NS, Johnson SC et al. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin Infect Dis 2005; 41: 236242.
  • 9
    Hosseinipour MC, Van Oosterhout JJ, Weigel R et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS (London, England) 2009; 23(9): 11271134.
  • 10
    Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447452.
  • 11
    Arribas JR, Pulido F, Delgado R et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40: 280287.
  • 12
    Pulido F, Delgado R, Perez-Valero I et al. Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother 2008; 61: 13591361.
  • 13
    Division of AIDS National Institutes of Health. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. Available at www3.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf (accessed 16 June 2009).
  • 14
    Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138145.
  • 15
    Braitstein P, Brinkhof MW, Dabis F et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817824.
  • 16
    Stringer JS, Zulu I, Levy J et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296: 782793.
  • 17
    Ferradini L, Jeannin A, Pinoges L et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367: 13351342.
  • 18
    Severe P, Leger P, Charles M et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353: 23252334.
  • 19
    Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (London, England) 2008; 22: 18971908.
  • 20
    Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 2008; 22: 13051312.
  • 21
    Hosseinipour MC, Neuhann FH, Kanyama CC et al. Lessons learned from a paying antiretroviral therapy service in the public health sector at Kamuzu Central Hospital, Malawi: 1-year experience. J Int Assoc Phys AIDS Care (Chicago, IL) 2006; 5: 103108.
  • 22
    Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (London, England) 2005; 19: 21412148.
  • 23
    Fairall LR, Bachmann MO, Louwagie GM et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med 2008; 168: 8693.
  • 24
    Madruga JV, Berger D, McMurchie M et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007; 370: 4958.
  • 25
    Deeks SG, Hoh R, Neilands TB et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005; 192: 15371544.
  • 26
    Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251260.
  • 27
    Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191201.
  • 28
    Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr 2006; 43: 278283.
  • 29
    Moore R, Gallant J. Renal Function after Use of Tenofovir as Part of the Initial ART Regimen. ICAAC/IDSA, Washington, DC, 2008.
  • 30
    Short WR, Solari P, Kaplan B. Comparison of Renal Function on NNRTI vs. Boosted PI Based Tenofovir Based Regimens. ICAAC/IDSA, Washington, DC, 2008.
  • 31
    Mallolas J, Sarasa M, Nomdedeu M et al. Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients. HIV Med 2007; 8: 131134.
  • 32
    Ribera E, Azuaje C, Lopez RM et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007; 59: 690697.
  • 33
    La Porte CJ, Colbers EP, Bertz R et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 15531560.
  • 34
    Nijland HM, L'Homme RF, Rongen GA et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22: 931935.
  • 35
    World Health Organization. 17th Expert Committee on the Selection and Use of Essential Medicines. 2009. Available at http://www.who.int/selection_medicines/committees/expert/17/en/index.html (accessed 6 July 2009).
  • 36
    Van Oosterhout JJ, Brown L, Weigel R et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009; 14(8): 856861.
  • 37
    Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22: 19711977.
  • 38
    Reynolds SJ, Nakigozi G, Newell K et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (London, England) 2009; 23: 697700.
  • 39
    Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371: 14431451.
  • 40
    Coutinho A, Mermin J, Ekwaru JP et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA 2008 [Abstract 125].
  • 41
    Mugyenyi P, Walker S, Hakim J et al., eds. Impact of routine laboratory monitoring over 5 years after antiretroviral therapy (ART) initiation on clinical disease progression of HIV-infected African adults: the DART Trial final results. 5th Conference on HIV Pathogenesis Treatment and Prevention. International AIDS Society, Cape Town, South Africa 2009 [Abstract TUSS102].
  • 42
    Lara AM, Kigozi J, Amurwon J et al., eds. Cost Effectiveness analysis of routine laboratory or clinically driven strategies for monitoring antiretroviral therapy in Uganda and Zimbabwe (DART trial). 5th Conference on HIV Pathogenesis Treatment and Prevention. International AIDS society, Cape Town, South Africa 2009 [Abstract TUSS103].